Client & Alumni News

Ben Franklin Client Cernostics Awarded Three Patents

Cernostics, a diagnostics company delivering next-generation cancer diagnostics through a unique approach to tissue analysis, announced that the United States Patent and Trademark Office has issued two patents, and the Japanese Patent Office a third patent, related to the TissueCypher™ Technology Platform. Most current diagnostic approaches offer a limited view of cancer, because they fail to evaluate the tumor as a system composed of multiple, interacting cell types. Cernostics’ patented technology is based on a tissue systems biology approach to anatomic pathology, simultaneously evaluating tumor, immune, and stromal cells, processes, and biomarkers on a single slide, while preserving and evaluating tissue structure. Read more: